LATEST ISSUE
Volume 1 · Issue 1 — October 2026
Submit news →
Latest issue
Covering July–October 2026
RAS finally blinks: daraxonrasib doubles survival in pancreatic cancer
Cover story · Clinical Updates
Editor's note — Welcome to the first ISOP Bulletin. This quarter has two sides for Pakistani oncologists. Abroad, RAS has been drugged in pancreatic cancer, and the ESR1 era has arrived in breast cancer. At home, newly priced immunotherapy waits for a notification, counterfeit vials keep turning up, and patients go without morphine.
IN THIS ISSUE
CLINICAL UPDATES
RAS-targeted therapy reaches pancreatic cancer
CLINICAL UPDATES
Oral SERDs and ESR1: two approvals in a fortnight
RESEARCH FROM PAKISTAN
Balochistan's unusual cancer map
REGULATORY WATCH
Priced but not available: pembrolizumab in Pakistan
COMMENT & CONTROVERSY
Galleri, ctDNA switching and failed confirmatory trials
MEETING COVERAGE
From LUMHS, Best of ASCO Lahore, WCLC Seoul and an ESMO preview
OFF THE RECORD
A glossary for the modern oncologist
REGULAR SECTIONS
Clinical Updates
Research from Pakistan
Regulatory Watch
Comment & Controversy
Meeting Coverage
Opportunities
Careers
Editorial
Honours
Off the Record
Calendar
In Memoriam
ARCHIVEAll issues
October 2026 · Vol 1 · Issue 1
The ISOP Bulletin — Breast Cancer Awareness Month
RAS-targeted therapy in pancreatic cancer, the ESR1 era in breast cancer, Balochistan's cancer map and pembrolizumab access in Pakistan.
Future issues will be listed here, newest first.
STAY INFORMED
Get each issue in your inbox
Published research from Pakistan, meeting coverage or an opportunity to share? Send it to the editorial team.